Taking TRIPS to India - Novartis, patent law, and access to medicines

Article Abstract:

Patients with cancer, lawyers for patient advocacy groups, and representatives of nongovernmental organizations (NGOs) converged, in August and September 2006, on the offices of Novartis in Mumbai, India to protest the company's efforts to obtain an Indian patent on the chronic myeloid leukemia treatment drug Gleevec. Novartis had filed a petition with the Chennai High Court challenging the Indian Patent Office's denial of a patent thus making the Gleevec challenge the latest controversy facing India since its January 1, 2005, implementation of substantially enhanced patent protection for pharmaceuticals.

Government regulation, India, Other Justice, Public Order, and Safety Activities, Patent Law, Switzerland, Novartis AG, Demonstrations and protests, Licensing, certification and accreditation, NVTSY

---

The pharmaceutical industry - prices and progress

Article Abstract:

Debate has raged over the economics of the pharmaceutical manufacturing industry with critics pointing to monopolistic pricing and high profits, defenders emphasize the advances in medical therapy achieved by the industry. However, the more pervasive and tougher price controls are, the lesser stimulus there will be to develop new, more effective medicines.

United States, Economic aspects

---

Similar abstracts:

• Abstracts: Dying at home: Supporting patient choices. Your choice
• Abstracts: Finding an obesity gene - a tale of mice and man. Genetic medicine and obesity
• Abstracts: The nursing of a patient following lung volume reduction surgery. Procedure for the assessment of lung function with spirometry
• Abstracts: Investigation of xerostomia in patients with rheumatoid arthritis. How can oral health care providers determine if patients have dry mouth?
• Abstracts: Demyelinating diseases - new pathological insights, new therapeutic targets. Molecular mimicry in multiple sclerosis

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.